Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New arthritis drug candidate AZD6912 begins first human safety tests

NCT ID NCT06115967

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a single dose of the experimental drug AZD6912 in 40 healthy adults to see if it is safe and how the body processes it. The study is a first step toward possibly treating rheumatoid arthritis, but it does not involve people with the disease. Results will help decide whether to test the drug in patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD6912
What this could lead to
If this drug is safe, it could lead to a new treatment option for rheumatoid arthritis.
What could go wrong
This is a very early Phase 1 trial in only 40 healthy people, not patients. It only tests safety and dosing, not whether the drug works for arthritis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

40 people

The number who actually took part.

Started

Nov 2023

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females must have a negative pregnancy test. * Contraceptive use by males and females should be consistent with local regulations. * Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg. * For optional Japanese participants only: * Participants must be of Japanese descent defined as: first generation (born to 2 Japanese parents and 4 Japanese grandparents). * Born in Japan, and not have lived outside Japan for more than 5 years. * Lifestyle, including diet, must not have significantly changed since leaving Japan. Exclusion Criteria: * History of any clinically important disease or disorder. * Current or recurrent disease of clinical significance that could affect clinical assessments or clinical laboratory evaluations. * Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention. * History of congenital or acquired immunodeficiency or complement deficiency or an underlying condition that predisposes to infection. * History of any Neisseria infection, unexplained, recurrent infections, or infection requiring treatment with systemic antibiotics. * Evidence of hepatitis B infection (positive for HBsAg or positive for anti-HBcAb) or hepatitis C viral infection (HCV Abs or hepatitis C RNA positive) or HIV infection (positive for HIV type 1 or type 2 Abs). * Participants testing positive for COVID-19 prior to dosing. * Any cardiac abnormalities. * A CAP activity \< 60% at screening. * Known or suspected history of drug abuse, history of alcohol abuse or smoking.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Research Site

    Montreal, Quebec, H3P 3P1, Canada

  • Research Site

    Harrow, HA1 3UJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.